Market capitalization | $17.86m |
Enterprise Value | $1.20m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.78 |
P/S ratio (TTM) P/S ratio | 11.67 |
P/B ratio (TTM) P/B ratio | 1.02 |
Sales growth (TTM) Sales growth | -27.48% |
Turnover (TTM) Turnover | $1.53m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
3 Analysts have issued a Lumos Pharma Inc forecast:
3 Analysts have issued a Lumos Pharma Inc forecast:
Dec '23 |
+/-
%
|
||
Net profit | -34 -34 |
10%
10%
|
|
Depreciation and amortization | 0.04 0.04 |
20%
20%
|
|
Share compensation | 2.32 2.32 |
0%
0%
|
|
Operating cash flow | -31 -31 |
17%
17%
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -31 -31 |
17%
17%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Head office | United States |
CEO | Richard Hawkins |
Employees | 33 |
Founded | 1999 |
Website | www.lumos-pharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.